Cyclic GMP in urine to monitor the response to ovarian cancer to therapy.
Guanosine 3':5'-phosphate (cycle GMP) in urine has been used to monitor the response of patients with ovarian cancer to treatment. Changes in the cyclic GMP level appear to correlate well with clinical status in that the disappearance of clinically detectable tumour is associated with a drop in the level whereas a tumour recurrence is associated with an elevation. Serially measured cyclic GMP is valuable for detecting a recurrence of tumour growth in patients in clinical remission and can predate any clinical signs by as much as 10 months. In patients who show no response to treatment, cyclic GMP levels in urine are elevated in the majority of specimens collected.
D003404:Creatinine / Q000652:urine; D006152:Cyclic GMP / Q000652:urine*; D003520:Cyclophosphamide / Q000008:administration & dosage; D003536:Cystadenocarcinoma / Q000188:drug therapy* / Q000652:urine; D004359:Drug Therapy, Combination; D005260:Female; D005866:Gestonorone Caproate / Q000008:administration & dosage; D006801:Humans; D007978:Levamisole / Q000627:therapeutic use; D009364:Neoplasm Recurrence, Local; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000652:urine
D007978:Levamisole; D003520:Cyclophosphamide; D003404:Creatinine; D006152:Cyclic GMP; D005866:Gestonorone Caproate